Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 29;23(5):731–742. doi: 10.1038/s41590-022-01187-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — Mice were infected with LCMV-Arm (2 × 10⁶ PFU/mouse) by i.v. injection and analyzed on day 8. a, Circulating virus titer (FFU: focus forming unit/ml, geometric mean ± s.d.) in the serum on day 8. (B6: n = 9, FlipFlop: n = 8, 4 independent experiments). b, Immunofluorescence staining of spleens on day 8 after infection. Staining with monoclonal antibodies specific for CD3 (red, T cells), IgD (blue, B cells), and VL-4 (white, LCMV) (n = 3 per strain, representative of 2 independent experiments). c, Virus-specific T cells in B6 and FlipFlop spleens were identified by H-2D^b/GP33 and I-A^b/GP66 viral tetramers and contained KLRG1⁺ cells (right) (n = 3 per strain, representative of 3 independent experiments). d, Virus-infected mixed BM chimeras. Circulating virus titers (FFU/ml, geometric mean ± s.d.) on day 8 after virus infection in the serum of mixed BM chimeras that were generated as in Extended Data Fig. 7b (B6: n = 7, FlipFlop: n = 7, FlipFlop Prf^KO: n = 6, 2 independent experiments). e, FlipFlop cytotoxic T cells prevent in vivo expansion of virus-specific B6 T cells. Graph indicates numbers of B6-origin H-2D^b/GP33-specific CD8 T cells (CD45.1) in spleens of mixed BM chimeras (day 8). Staining profiles and gate are shown in Extended Data Fig. 7d,e (group 1: n = 3, group 2: n = 4, group 3: n = 4, 2 independent experiments). f, In vivo FlipFlop cytotoxic T cells prevent in vitro activation of virus-specific B6 CD8 T cells. In vitro GP33 peptide stimulation of splenocytes from infected mixed BM chimeras (day 8) were assessed for IFNγ⁺ induction of B6-origin CD8 T cells (CD45.1). Staining profiles are shown in Extended Data Fig. 7f (group 1: n = 3, group 2: n = 4, group 3: n = 4, 2 independent experiments). g, Impact of FlipFlop T cells on numbers of B cells and GC B cells in the spleen from infected mixed BM chimeras. Spleens from infected mixed BM chimeras (day 8) were assessed for numbers of CD45.1 B6-origin B cells (B220⁺; left) and GC B cells (GL7⁺FAS⁺; right) (n = 5/group, 2 independent experiments). *P < 0.05, **P < 0.01, ***P < 0.001 (Mann–Whitney two-tailed unpaired test for a and d, two-tailed unpaired t-test for e–g); mean ± s.e.m. (e–g).